Genomic features of the human dopamine transporter gene and its potential epigenetic states: Implications for phenotypic diversity

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Shumay, Elena ^a   Fowler, Joanna S ^a   Volkow, Nora D ^b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; MESSENGER RNA; MICRORNA;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DOPAMINERGIC SYSTEM; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MUTATIONAL ANALYSIS; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; VARIABLE NUMBER OF TANDEM REPEAT; GENETIC EPIGENESIS; GENETICS; PHENOTYPE;

DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EPIGENESIS, GENETIC; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77956216735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011067     Document Type: Article

References (147)

1. Mehler-Wex C, Riederer P, Gerlach M (2006) Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 10: 167-179.
2. Greenwood TA, Schork NJ, Eskin E, Kelsoe JR (2006) Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 11: 125-133, 115.
3. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, et al. (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409: 38-56.
4. Bannon MJ, Whitty CJ (1997) Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48: 969-977.
5. Zahniser NR, Sorkin A (2004) Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47 Suppl 1: 80-91.
6. Volkow ND, Wang G-J, Fowler JS, Ding Y-S (2005) Imaging the Effects of Methylphenidate on Brain Dopamine: New Model on Its Therapeutic Actions for Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry 57: 1410-1415.
7. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, et al. (2007) Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17: 39-59.
8. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, et al. (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452-2458.
9. Cruz-Muros I, Afonso-Oramas D, Abreu P, Perez-Delgado MM, Rodriguez M, et al. (2009) Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol Aging 30: 973-986.
10. Haddley K, Vasiliou AS, Ali FR, Paredes UM, Bubb VJ, et al. (2008) Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem Res 33: 652-667.
11. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, et al. (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14: 1104-1106.
12. Greenwood TA, Alexander M, Keck PE, McElroy S, Sadovnick AD, et al. (2002) Segmental linkage disequilibrium within the dopamine transporter gene. Mol Psychiatry 7: 165-173.
13. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, et al. (2008) Decreased dopamine transporter availability in male smokers - a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 32: 274-279.
14. Samochowiec J, Kucharska-Mazur J, Grzywacz A, Jablonski M, Rommelspacher H, et al. (2006) Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence. Neurosci Lett 410: 1-5.
15. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, et al. (2000) Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133-139.
16. Krause J, Dresel SH, Krause KH, La Fougere C, Zill P, et al. (2006) Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World J Biol Psychiatry 7: 152-157.
17. Jaffee SR, Price TS (2007) Gene-environment correlations: a review of the evidence and implications for prevention of mental illness. Mol Psychiatry 12: 432-442.
18. McGowan PO, Meaney MJ, Szyf M (2008) Diet and the epigenetic (re)programming of phenotypic differences in behavior. Brain Res 1237: 12-24.
19. Cirulli F, Francia N, Berry A, Aloe L, Alleva E, et al. (2009) Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. Neurosci Biobehav Rev 33: 573-585.
20. Frohna PA, Neal-Beliveau BS, Joyce JN (1997) Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions. Synapse 25: 293-305.
21. Stevens SE, Kumsta R, Kreppner JM, Brookes KJ, Rutter M, et al. (2009) Dopamine transporter gene polymorphism moderates the effects of severe deprivation on ADHD symptoms: developmental continuities in geneenvironment interplay. Am J Med Genet B Neuropsychiatr Genet 150B: 753-761.
22. Duret L, Galtier N (2009) Biased Gene Conversion and the Evolution of Mammalian Genomic Landscapes. Annu Rev Genomics Hum Genet.
23. Hurst LD (2009) Evolutionary genomics: A positive becomes a negative. Nature 457: 543-544.
24. Marques-Bonet T, Kidd JM, Ventura M, Graves TA, Cheng Z, et al. (2009) A burst of segmental duplications in the genome of the African great ape ancestor. Nature 457: 877-881.
25. Kehrer-Sawatzki H, Cooper DN (2007) Understanding the recent evolution of the human genome: insights from human-chimpanzee genome comparisons. Hum Mutat 28: 99-130.
26. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 848-853.
27. Vandenbergh DJ, Thompson MD, Cook EH, Bendahhou E, Nguyen T, et al. (2000) Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol Psychiatry 5: 283-292.
28. Ninio J (2006) Multiple stages in codon-anticodon recognition:double-trigger mechanisms and geometric constraints. Biochimie 88: 963-992.
29. Okazaki N, Imai K, Kikuno RF, Misawa K, Kawai M, et al. (2005) Influence of the 39-UTR-length of mKIAA cDNAs and their Sequence Features to the mRNA Expression Level in the Brain. DNA Res 12: 181-189.
30. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, et al. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205-216.
31. Sethupathy P, Giang H, Plotkin JB, Hannenhalli S (2008) Genome-wide analysis of natural selection on human cis-elements. PLoS ONE 3: e3137.
32. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A ''silent'' polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
33. Murphy FVt, Ramakrishnan V, Malkiewicz A, Agris PF (2004) The role of modifications in codon discrimination by tRNA(Lys)UUU. Nat Struct Mol Biol 11: 1186-1191.
34. Semon M, Duret L (2006) Evolutionary origin and maintenance of coexpressed gene clusters in mammals. Mol Biol Evol 23: 1715-1723.
35. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. Cancer Res 67: 9609-9612.
36. O'Dushlaine C, Shields D (2008) Marked variation in predicted and observed variability of tandem repeat loci across the human genome. BMC Genomics 9: 175.
37. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575-621.
38. Vinces MD, Legendre M, Caldara M, Hagihara M, Verstrepen KJ (2009) Unstable tandem repeats in promoters confer transcriptional evolvability. Science 324: 1213-1216.
39. Lim MH, Kim HW, Paik KC, Cho SC, Yoon DY, et al. (2006) Association of the DAT1 polymorphism with attention deficit hyperactivity disorder (ADHD): a family-based approach. Am J Med Genet B Neuropsychiatr Genet 141B: 309-311.
40. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, et al. (2006) A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A 103: 4552-4557.
41. O'Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, et al. (2007) Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 17: 61-67.
42. Benson G (1999) Tandem repeats finder: a program to analyze DNA sequences. Nucleic Acids Res 27: 573-580.
43. Boeva V, Regnier M, Papatsenko D, Makeev V (2006) Short fuzzy tandem repeats in genomic sequences, identification, and possible role in regulation of gene expression. Bioinformatics 22: 676-684.
44. Denoeud F, Vergnaud G, Benson G (2003) Predicting human minisatellite polymorphism. Genome Res 13: 856-867.
45. Legendre M, Pochet N, Pak T, Verstrepen KJ (2007) Sequence-based estimation of minisatellite and microsatellite repeat variability. Genome Res 17: 1787-1796.
46. Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA (2008) Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet 40: 1199-1203.
47. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, et al. (2009) Origins and functional impact of copy number variation in the human genome. Nature advance online publication.
48. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
49. Dear PH (2009) Copy-number variation: the end of the human genome? Trends Biotechnol 27: 448-454.
50. Bailey JA, Eichler EE (2006) Primate segmental duplications: crucibles of evolution, diversity and disease. Nat Rev Genet 7: 552-564.
51. Cheng Z, Ventura M, She X, Khaitovich P, Graves T, et al. (2005) A genomewide comparison of recent chimpanzee and human segmental duplications. Nature 437: 88-93.
52. Drgon T, Lin Z, Wang GJ, Fowler J, Pablo J, et al. (2006) Common human 59 dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 26: 875-889.
53. Martinat C, Bacci J-J, Leete T, Kim J, Vanti WB, et al. (2006) Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proceedings of the National Academy of Sciences of the United States of America 103: 2874-2879.
54. Alberini CM (2009) Transcription factors in long-term memory and synaptic plasticity. Physiol Rev 89: 121-145.
55. Dolfini D, Zambelli F, Pavesi G, Mantovani R (2009) A perspective of promoter architecture from the CCAAT box. Cell Cycle 8: 4127-4137.
56. Zhang MQ (2005) Using CorePromoter to find human core promoters. Curr Protoc Bioinformatics Chapter 2: Unit 2 9.
57. Thierry-Mieg D, Thierry-Mieg J (2006) AceView: a comprehensive cDNAsupported gene and transcripts annotation. Genome Biol 7 Suppl 1: S12 11-14.
58. Finotti A, Treves S, Zorzato F, Gambari R, Feriotto G (2008) Upstream stimulatory factors are involved in the P1 promoter directed transcription of the A beta H-J-J locus. BMC Mol Biol 9: 110.
59. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, et al. (2006) Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet 38: 626-635.
60. Schulz R, McCole RB, Woodfine K, Wood AJ, Chahal M, et al. (2009) Transcript- and tissue-specific imprinting of a tumour suppressor gene. Hum Mol Genet 18: 118-127.
61. Lammel S, Hetzel A, Hackel O, Jones I, Liss B, et al. (2008) Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57: 760-773.
62. Vandenbergh DJ, Persico AM, Uhl GR (1992) A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res 15: 161-166.
63. Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB (1994) Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol 45: 125-135.
64. Lin JC, Thirumalai D (2008) Relative stability of helices determines the folding landscape of adenine riboswitch aptamers. J Am Chem Soc 130: 14080-14081.
65. Ringner M, Krogh M (2005) Folding free energies of 59-UTRs impact posttranscriptional regulation on a genomic scale in yeast. PLoS Comput Biol 1: e72.
66. Ozsarac N, Santha E, Hoffman BJ (2002) Alternative non-coding exons support serotonin transporter mRNA expression in the brain and gut. Journal of Neurochemistry 82: 336-344.
67. Ma Q (2006) Transcriptional regulation of neuronal phenotype in mammals. J Physiol 575: 379-387.
68. Wang J, Bannon MJ (2005) Sp1 and Sp3 activate transcription of the human dopamine transporter gene. J Neurochem 93: 474-482.
69. Frith MC, Li MC, Weng Z (2003) Cluster-Buster: Finding dense clusters of motifs in DNA sequences. Nucleic Acids Res 31: 3666-3668.
70. Robertson G, Bilenky M, Lin K, He A, Yuen W, et al. (2006) cisRED: a database system for genome-scale computational discovery of regulatory elements. Nucleic Acids Res 34: D68-73.
71. Verma A, Yadav VK, Basundra R, Kumar A, Chowdhury, S (2009) Evidence of genome-wide G4 DNA-mediated gene expression in human cancer cells. Nucleic Acids Res.
72. Lane AN, Chaires JB, Gray RD, Trent JO (2008) Stability and kinetics of Gquadruplex structures. Nucleic Acids Res 36: 5482-5515.
73. Kikin O, Zappala Z, D'Antonio L, Bagga PS (2008) GRSDB2 and GRS_UTRdb: databases of quadruplex forming G-rich sequences in premRNAs and mRNAs. Nucl Acids Res 36: D141-148.
74. Kumari S, Bugaut A, Huppert JL, Balasubramanian S (2007) An RNA Gquadruplex in the 59 UTR of the NRAS proto-oncogene modulates translation. Nat Chem Biol 3: 218-221.
75. Didiot MC, Tian Z, Schaeffer C, Subramanian M, Mandel JL, et al. (2008) The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer. Nucleic Acids Res 36: 4902-4912.
76. Barlati S, Barbon A (2005) RNA editing: a molecular mechanism for the fine modulation of neuronal transmission. Acta Neurochir Suppl 93: 53-57.
77. Price RD, Sanders-Bush E (2000) RNA editing of the human serotonin 5- HT(2C) receptor delays agonist-stimulated calcium release. Mol Pharmacol 58: 859-862.
78. Kuyumcu-Martinez NM, Cooper TA (2006) Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol 44: 133-159.
79. Andken BB, Lim I, Benson G, Vincent JJ, Ferenc MT, et al. (2007) 39-UTR SIRF: a database for identifying clusters of whort interspersed repeats in 39 untranslated regions. BMC Bioinformatics 8: 274.
80. Aranda-Abreu GE, Hernandez ME, Soto A, Manzo J (2005) Possible Cisacting signal that could be involved in the localization of different mRNAs in neuronal axons. Theor Biol Med Model 2: 33.
81. Kremerskothen J, Kindler S, Finger I, Veltel S, Barnekow A (2006) Postsynaptic recruitment of Dendrin depends on both dendritic mRNA transport and synaptic anchoring. J Neurochem 96: 1659-1666.
82. Corral-Debrinski M (2007) mRNA specific subcellular localization represents a crucial step for fine-tuning of gene expression in mammalian cells. Biochim Biophys Acta 1773: 473-475.
83. Chiaruttini C, Vicario A, Li Z, Baj G, Braiuca P, et al. (2009) Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc Natl Acad Sci U S A 106: 16481-16486.
84. Abdel-Ghany M, el-Gendy K, Zhang S, Raden D, Racker E (1989) Brain protein kinase C phosphorylating poly(arginine,serine) or lamin B is stimulated by anions and by an activator purified from bovine serum albumin preparations. Proc Natl Acad Sci U S A 86: 1761-1765.
85. Crayton ME, 3rd, Powell BC, Vision TJ, Giddings MC (2006) Tracking the evolution of alternatively spliced exons within the Dscam family. BMC Evol Biol 6: 16.
86. Cusack BP, Wolfe KH (2005) Changes in alternative splicing of human and mouse genes are accompanied by faster evolution of constitutive exons. Mol Biol Evol 22: 2198-2208.
87. Chen M, Manley JL (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10: 741-754.
88. Chinta SJ, Pai HV, Ravindranath V (2005) Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver. Brain Res Mol Brain Res 135: 81-92.
89. Tzvetkov MV, Meineke C, Oetjen E, Hirsch-Ernst K, Brockmoller J (2007) Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene 386: 52-62.
90. Stamm S (2008) Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem 283: 1223-1227.
91. Loria PM, Duke A, Rand JB, Hobert O (2003) Two neuronal, nuclearlocalized RNA binding proteins involved in synaptic transmission. Curr Biol 13: 1317-1323.
92. Rahman L, Bliskovski V, Reinhold W, Zajac-Kaye M (2002) Alternative splicing of brain-specific PTB defines a tissue-specific isoform pattern that predicts distinct functional roles. Genomics 80: 245-249.
93. Nairn AC, Greengard P (2001) A novel cyclin provides a link between dopamine and RNA processing. Neuron 32: 174-176.
94. Zhou HL, Baraniak AP, Lou H (2007) Role for Fox-1/Fox-2 in mediating the neuronal pathway of calcitonin/calcitonin gene-related peptide alternative RNA processing. Mol Cell Biol 27: 830-841.
95. Yeo GW, Coufal NG, Liang TY, Peng GE, Fu X-D, et al. (2009) An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Nat Struct Mol Biol 16: 130-137.
96. Kuroyanagi H (2009) Fox-1 family of RNA-binding proteins. Cell Mol Life Sci 66: 3895-3907.
97. Nissim-Rafinia M, Kerem B (2006) Splicing modulation as a modifier of the CFTR function. Prog Mol Subcell Biol 44: 233-254.
98. Kim SR, Sai K, Tanaka-Kagawa T, Jinno H, Ozawa S, et al. (2007) Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos 35: 1865-1872.
99. Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, et al. (2007) Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 110: 1055-1063.
100. Zhang XH, Chasin LA (2006) Comparison of multiple vertebrate genomes reveals the birth and evolution of human exons. Proc Natl Acad Sci U S A 103: 13427-13432.
101. Licatalosi DD, Darnell RB (2006) Splicing regulation in neurologic disease. Neuron 52: 93-101.
102. Carlini DB, Genut JE (2006) Synonymous SNPs provide evidence for selective constraint on human exonic splicing enhancers. J Mol Evol 62: 89-98.
103. Hebert SS, De Strooper B (2007) Molecular biology. miRNAs in neurodegeneration. Science 317: 1179-1180.
104. Wang E (2007) MicroRNA, the putative molecular control for mid-life decline. Ageing Res Rev 6: 1-11.
105. Ibanez-Ventoso C, Yang M, Guo S, Robins H, Padgett RW, et al. (2006) Modulated microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell 5: 235-246.
106. Vasudevan S, Tong Y, Steitz JA (2007) Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931-1934.
107. Kawahara Y, Zinshteyn B, Sethupathy P, Iizasa H, Hatzigeorgiou AG, et al. (2007) Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 315: 1137-1140.
108. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, et al. (2009) New class of microRNA targets containing simultaneous 59-UTR and 39-UTR interaction sites. Genome Res 19: 1175-1183.
109. Chen JM, Ferec C, Cooper DN (2006) A systematic analysis of diseaseassociated variants in the 39 regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 39 UTR variants. Hum Genet 120: 301-333.
110. Kozak M (2005) Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 361: 13-37.
111. Mill J, Asherson P, Browes C, D'Souza U, Craig I (2002) Expression of the dopamine transporter gene is regulated by the 39 UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114: 975-979.
112. Brodskii LI, Ivanov VV, Kalaidzidis Ia L, Leontovich AM, Nikolaev VK, et al. (1995) [GeneBee-NET: An Internet based server for biopolymer structure analysis]. Biokhimiia 60: 1221-1230.
113. Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, et al. (2008) Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 312: 131-138.
114. Wang Y, Leung FC (2004) An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 20: 1170-1177.
115. Levenson JM, Roth TL, Lubin FD, Miller CA, Huang IC, et al. (2006) Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 281: 15763-15773.
116. Nelson ED, Kavalali ET, Monteggia LM (2008) Activity-dependent suppression of miniature neurotransmission through the regulation of DNA methylation. J Neurosci 28: 395-406.
117. Miller CA, Campbell SL, Sweatt JD (2008) DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol Learn Mem 89: 599-603.
118. Simmen MW (2008) Genome-scale relationships between cytosine methylation and dinucleotide abundances in animals. Genomics 92: 33-40.
119. Bock C, Lengauer T (2008) Computational epigenetics. Bioinformatics 24: 1-10.
120. Cooper SJ, Trinklein ND, Anton ED, Nguyen L, Myers RM (2006) Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. Genome Res 16: 1-10.
121. Illingworth R, Kerr A, Desousa D, Jorgensen H, Ellis P, et al. (2008) A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol 6: e22.
122. Varriale A, Bernardi G (2006) DNA methylation and body temperature in fishes. Gene 385: 111-121.
123. Jiang C, Han L, Su B, Li WH, Zhao Z (2007) Features and trend of loss of promoter-associated CpG islands in the human and mouse genomes. Mol Biol Evol 24: 1991-2000.
124. Zelko IN, Mueller MR, Folz RJ (2008) Transcription factors sp1 and sp3 regulate expression of human extracellular superoxide dismutase in lung fibroblasts. Am J Respir Cell Mol Biol 39: 243-251.
125. Choi JK, Kim YJ (2008) Epigenetic regulation and the variability of gene expression. Nat Genet 40: 141-147.
126. Radwan A, Younis A, Luykx P, Khuri S (2008) Prediction and analysis of nucleosome exclusion regions in the human genome. BMC Genomics 9: 186.
127. Kouzarides, T (2007) Chromatin modifications and their function. Cell 128: 693-705.
128. Oki M, Aihara H, Ito T (2007) Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Subcell Biochem 41: 319-336.
129. Kass SU, Wolffe AP (1998) DNA methylation, nucleosomes and the inheritance of chromatin structure and function. Novartis Found Symp 214: 22-35; discussion 36-50.
130. Santos-Reboucas CB, Pimentel MM (2007) Implication of abnormal epigenetic patterns for human diseases. Eur J Hum Genet 15: 10-17.
131. Colvis CM, Pollock JD, Goodman RH, Impey S, Dunn J, et al. (2005) Epigenetic mechanisms and gene networks in the nervous system. J Neurosci 25: 10379-10389.
132. Michopoulos I, Douzenis A, Christodoulou C, Lykouras L (2006) Topiramate use in alprazolam addiction. World J Biol Psychiatry 7: 265-267.
133. Myrick H, Brady KT (2003) The use of divalproex in the treatment of addictive disorders. Psychopharmacol Bull 37 Suppl 2: 89-97.
134. Reid MS, Casadonte P, Baker S, Sanfilipo M, Braunstein D, et al. (2005) A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 100 Suppl 1: 43-57.
135. Wang J, Michelhaugh SK, Bannon MJ (2007) Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur J Neurosci 25: 1982-1986.
136. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA (2003) Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 53: 352-359.
137. Duret L, Galtier N (2009) Biased gene conversion and the evolution of mammalian genomic landscapes. Annu Rev Genomics Hum Genet 10: 285-311.
138. Levdansky E, Romano J, Shadkchan Y, Sharon H, Verstrepen KJ, et al. (2007) Coding tandem repeats generate diversity in Aspergillus fumigatus genes. Eukaryot Cell 6: 1380-1391.
139. Verstrepen KJ, Jansen A, Lewitter F, Fink GR (2005) Intragenic tandem repeats generate functional variability. Nat Genet 37: 986-990.
140. Nguyen DQ, Webber C, Hehir-Kwa J, Pfundt R, Veltman J, et al. (2008) Reduced purifying selection prevails over positive selection in human copy number variant evolution. Genome Res 18: 1711-1723.
141. Chiang CW, Derti A, Schwartz D, Chou MF, Hirschhorn JN, et al. (2008) Ultraconserved elements: analyses of dosage sensitivity, motifs and boundaries. Genetics 180: 2277-2293.
142. Burt SA, Mikolajewski AJ (2008) Preliminary evidence that specific candidate genes are associated with adolescent-onset antisocial behavior. Aggress Behav 34: 437-445.
143. Gizer IR, Ficks C, Waldman ID (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126: 51-90.
144. van der Zwaluw CS, Engels RC, Buitelaar J, Verkes RJ, Franke B, et al. (2009) Polymorphisms in the dopamine transporter gene (SLC6A3/DAT1) and alcohol dependence in humans: a systematic review. Pharmacogenomics 10: 853-866.
145. Wonodi I, Hong LE, Stine OC, Mitchell BD, Elliott A, et al. (2009) Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 150B: 282-289.
146. VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6: 55.
147. Forbes EE, Brown SM, Kimak M, Ferrell RE, Manuck SB, et al. (2009) Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry 14: 60-70.